← All trials
NCT07146997
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2023
- Primary completion
- Nov 23, 2024
- Completion date
- Nov 23, 2024
- First posted
- Aug 28, 2025
- Last posted
- Sep 9, 2025
- Enrollment
- 96
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HITEC-Institute of Medical SciencesLead sponsor
- HITEC-Institute of Medical SciencesCollaborator
- HITEC-Institute of Medical SciencesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.